# A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00391729** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 221 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** ABT-089
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00391729
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2011-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391729, "A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00391729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*